Take-Home Message: Ibrutinib Approved for All CLL Patients

Description: Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology argues that the take-home message for the follow-up on the RESONATE trial is the role of ibrutinib for all types of CLL patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.
Shared By : AnnualMeeting2017
Posted on : 06/15/17
Added : 5 months ago


Nothing found.

More From AnnualMeeting2017

Nothing found.